LETTER TO THE EDITOR

Is there a link between amyotrophic lateral sclerosis and treatment with TNF-alpha inhibitors?

A. BÖRJESSON¹, B. GRUNDMARK¹,², H. OLAISSON¹ & L. WALDENLIND¹

¹Department of Pharmacovigilance, Medical Products Agency, Uppsala, Sweden, and ²Department of Surgical Sciences, Uppsala University, Uppsala, Sweden

The pan-European database EudraVigilance database (EVD) contains all serious adverse drug reaction (ADR) reports for all drugs approved within the European Union. In our routine signal detection in EVD, we have observed a cluster of reports of amyotrophic lateral sclerosis (ALS) in relation to treatment with TNF-alpha inhibitors, mainly used in rheumatoid arthritis (RA). The number of reported cases on 15 December 2012 was established to be between 58 and 73 (Table I). The uncertainty in exact numbers is due to possible duplicate reporting. In five of the reports more than one TNF-alpha blocker were reported as suspected drug. The cases originated from 14 different countries. In comparison, the highest number of reported ALS cases in EVD, in relation to any other drug indicated for the use in RA, was found for methotrexate with three cases. In literature three cases of ALS during TNF-alpha blockade treatment have been described (1-3).

Biological substances including the TNF-alpha blockers are less frequently used (~20% of patients) in RA treatment compared with methotrexate (86%), prednisone (72%), sulfasalazine (46%), and chloroquine phosphate/hydroxychloroquine (42%) (4-6). If the spontaneously reported ALS cases in relation to TNF-alpha inhibitor treatment were a result of confounding by indication, age, severity of suspected adverse drug reaction, or by novelty and special attention to biological substances, the number of cases for other RA-indicated products including biological substances, as well as other biological substances.

Under-reporting of ADRs is extensive, and estimation of the true incidence of a particular ADR in association with a certain drug is not possible from spontaneous reporting. It has been estimated that on average only 1 of every 20 occurring ADRs is being reported (8,9). The incidence of ALS associated with the TNF-alpha blockers was estimated from the number of cases and available drug exposure data. It was found to be close to the background incidence of approximately 2 cases per 100,000 individuals annually (10). Consequently, the true incidence of ALS with TNF-alpha inhibitory treatment would reach a level above the background incidence. ALS affects the central nervous system, and diagnosis in the reported cases was based on clinical symptoms of progressive motor neuron degeneration confirmed by electrophysiological or neuropathological findings. It is invariably fatal.

TNF-alpha is a major regulator of complex physiological processes within the central nervous system.
Acknowledged ADRs of TNF-alpha inhibitor therapy already include nervous system disorders such as onset of or exacerbation of central nervous system demyelization disorders, including multiple sclerosis, and peripheral demyelization disorders. Two types of TNF-alpha receptors have been described in the literature. Depending on the context, TNF-alpha receptor activation is associated with neuro-protection, stimulation of neurogenesis, axonogenesis and synaptic plasticity (12,13), with associated protection of neurons from neurotoxic milieus such as oxidative stress (14) and glutamate or nitric oxide overload (15,16). Thus, a physiologically plausible mechanism exists in the reported cases explaining why ALS may have been caused by loss of or decreased neuronal protection by TNF-alpha activation.

This pharmacovigilance signal of disproportionate reporting in a public database of ALS in relation to treatment with TNF-alpha inhibitors merits further investigation for a causal relation to be confirmed or refuted.

Results and views of the presented study represent the authors and not necessarily any official views of the Swedish Medical Products Agency where the authors are (partly) employed.

References

1. Dziadzio M, Reddy V, Rahman S, Mummery C, Keat A. Is TNFα a good therapeutic target in motoneuronal degeneration? A case of amyotrophic lateral sclerosis in a patient with RA receiving infliximab. Rheumatology. 2006;45:1445–6.
2. Loustau V, Foltz V, Poulain C, Rozenberg S. Diagnosis of amyotrophic lateral sclerosis in a patient treated with TNFα blockers for ankylosing spondylitis: fortuitous association or new side effects of TNFα blockers? Joint Bone Spine. 2009;76:213–14.
3. Padovan M, Caniatti LM, Trotta F, Govoni M. Concomitant rheumatoid arthritis and amyotrophic lateral sclerosis: report of two cases and review of literature. Rheumatol Int. 2011;31:715–19.
4. Sokk T, Envalds M, Pincus T. Treatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugs. Mod Rheumatol. 2008;18:228–39.
5. Grigelva CG, Chung CP, Stein CM, Mitchel EF Jr, Griffin MR. Changing patterns of medication use in patients with rheumatoid arthritis in a Medicaid population. Rheumatology (Oxford). 2008;47:1001–4.
6. Ziegler S, Huscher D, Karberg K, Krause A, Wassenberg S, Zink A. Trends in treatment and outcomes of rheumatoid arthritis in Germany 1997–2007: results from the National Database of the German Collaborative Arthritis Centres. Ann Rheum Dis. 2010;69:1803–8.
7. Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain. 1995;118:707–19.
8. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29:385–96.
9. Begaud B, Martin K, Haramburu F, Moore N. Rates of spontaneous reporting of adverse drug reactions in France. JAMA. 2002;288:1588.
10. Logroscino G, Traynor BJ, Hardiman O, Chiò A, Mitchell D, Swingler RJ, et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2010;81:385–90.
11. Park KM, Bowers WJ. Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction. Cell Signal. 2010;22:977–83.
12. Figiel I. Pro-inflammatory cytokine TNF-alpha as a neuroprotective agent in the brain. Acta Neurobiol Exp (Wars). 2008;68:526–34.
13. Montgomery SL, Bowers WJ. Tumor necrosis factor-alpha and the roles it plays in homeostatic and degenerative processes within the central nervous system. J Neuroimmune Pharmacol. 2012;7:42–59.
14. Fischer R, Maier O, Siegemund M, Wajant H, Scheurich P, Pietznauer K. A TNF receptor 2 selective agonist rescues human neurons from oxidative stress-induced cell death. PLoS ONE. 2011;6:e27621.
15. Dolga AM, Granic I, Blank T, Knaus HG, Spiess J, Luiten PG. TNF-alpha mediates neuroprotection against glutamate-induced excitotoxicity via NF-kappB-dependent up-regulation of K2.2 channels. J Neurochem. 2008;107:1158–67.
16. Turrin NP, Rivest S. Tumor necrosis factor alpha but not interleukin 1 beta mediates neuroprotection in response to acute nitric oxide excitotoxicity. J Neurosci. 2006;26:143–51.